Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.

OBJECTIVE The purpose of this study is to retrospectively evaluate the relationships between the BRCA mutation types, imaging features, and pathologic findings of breast cancers in BRCA1 and BRCA2 mutation carriers. MATERIALS AND METHODS We identified patients with breast cancer with BRCA gene mutations from January 2000 to December 2014. After excluding patients who underwent lesion excision before MRI, 99 BRCA1 and 103 BRCA2 lesions in 187 women (mean age, 39.7 and 40.4 years, respectively) were enrolled. Mammographic, sonographic, and MRI scans were reviewed according to the BI-RADS lexicon (5th edition). Pathologic data were reviewed, including the immunohistochemistry findings. The relationships between the BRCA mutations and both imaging and pathologic findings were analyzed. RESULTS The distribution of molecular subtypes of tumors significantly differed by the mutation type. BRCA1 tumors were associated with the triple-negative subtype, whereas BRCA2 tumors were associated with the luminal B subtype (p = 0.002). At MRI, breast cancers with BRCA1 mutations exhibited a circumscribed margin (p = 0.032) and rim enhancement (p = 0.013). No significant differences in mass shape or kinetic features were observed at MRI. Cancers in BRCA1 mutation carriers tended to develop in the posterior location in the breast (p = 0.034). At mammography, no significant difference in the prevalence of calcifications was observed according to the mutation type. At sonography, BRCA1 lesions were found to be associated with posterior acoustic enhancement (p < 0.0001). CONCLUSION Breast cancers with BRCA1 mutations tend to exhibit benign morphologic features at MRI, mammography, and sonography, compared with BRCA2 mutations. Lesion location may represent another difference on imaging among various genetic phenotypes.

[1]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[2]  C. Kuhl,et al.  Mammographic, US, and MR imaging phenotypes of familial breast cancer. , 2008, Radiology.

[3]  C. Wells,et al.  Correlation between ultrasound characteristics, mammographic findings and histological grade in patients with invasive ductal carcinoma of the breast. , 2000, Clinical radiology.

[4]  T. Uematsu,et al.  Triple-negative breast cancer: correlation between MR imaging and pathologic findings. , 2009, Radiology.

[5]  J. C. Marcus,et al.  Sonographic appearance of invasive ductal carcinoma of the breast according to histologic grade. , 2012, AJR. American journal of roentgenology.

[6]  J. Lee,et al.  Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation , 2013, Journal of breast cancer.

[7]  Magnetic Resonance Imaging of Breast Cancer Patients with BRCA Mutation , 2013 .

[8]  Mads Thomassen,et al.  Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling , 2013, PloS one.

[9]  D Krebs,et al.  Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. , 2000, Radiology.

[10]  R. Fimmers,et al.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Christopher I Amos,et al.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[14]  Fiona J Gilbert,et al.  Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. , 2009, Radiology.

[15]  Harry J de Koning,et al.  BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Visscher,et al.  Centrally Necrotizing Carcinomas of the Breast: A Distinct Histologic Subtype With Aggressive Clinical Behavior , 2001, The American journal of surgical pathology.

[17]  D B Plewes,et al.  Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[19]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[20]  Jeong Eon Lee,et al.  Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients , 2011, Breast Cancer Research and Treatment.

[21]  Bruce L Daniel,et al.  Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. , 2006, JAMA.

[22]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[23]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .

[24]  S. Heywang-Köbrunner,et al.  Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results , 2008 .

[25]  R. Mann,et al.  Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI , 2008, European Radiology.

[26]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[27]  Won Hwa Kim,et al.  Location of Triple-Negative Breast Cancers: Comparison with Estrogen Receptor-Positive Breast Cancers on MR Imaging , 2015, PloS one.

[28]  A. Bowcock,et al.  Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. , 1997, The New England journal of medicine.

[29]  Shuangqing Liu,et al.  Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis , 2018, Front. Pharmacol..

[30]  Theo van der Kwast,et al.  A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false‐negative mammography , 2002, International journal of cancer.

[31]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.